1612786-29-4

Upstream product

• 1431473-24-3 (2R,5S)-benzyl 5-hydroxy-2-methylpiperidine-1-carboxylate 
• 124-63-0 methanesulfonyl chloride 
• 501-53-1 benzyl chloroformate 
• 54751-93-8 6-methyl-3-piperidinol 
• 1121-78-4 5-Hydroxy-2-methylpyridine 
• 1314396-07-0 (±)-benzyl 5-hydroxy-2-methylpiperidine-1-carboxylate 
• 1314395-91-9 (±)-benzyl 2-methyl-5-oxopiperidine-1-carboxylate 

Downstream Products

• 1207853-72-2 benzyl (2R,5R)-5-amino-2-methyl-piperidine-1-carboxylate 
• 1222491-53-3 tert-butyl ((3R,6R)-6-methylpiperidin-3-yl)carbamate 
• 1612786-33-0 tert-butyl ((3R,6R)-1-(2-(2H-1,2,3-triazol-2-yl)benzoyl)-6-methylpiperidin-3-yl)carbamate 
• 1612786-54-5 (2-(2H-1,2,3-triazol-2-yl)phenyl)((2R,5R)-5-amino-2-methylpiperidin-1-yl)methanone 
• 1612786-14-7 2-(((3R,6R)-1-(2-(2H-1,2,3-triazol-2-yl)benzoyl)-6-methylpiperidin-3-yl)amino)isonicotinonitrile 
• 1612786-34-1 (2R,5R)-benzyl 5-((4-cyanopyridin-2-yl)amino)-2-methylpiperidine-1-carboxylate 
• 1612786-16-9 2-(((3R,6R)-1-(2-(2H-tetrazol-2-yl)benzoyl)-6-methylpiperidin-3-yl)amino)isonicotinonitrile 
• 1612786-47-6 (2R,5R)-benzyl 5-(4-cyano-3-methoxypyridin-2-ylamino)-2-methylpiperidine-1-carboxylate 
• 1612786-21-6 2-(((3R,6R)-1-(2-(2H-1,2,3-triazol-2-yl)benzoyl)-6-methylpiperidin-3-yl)(methyl)amino)isonicotinonitrile 
• 1612786-28-3 N-((3R,6R)-1-(2-(2H-1,2,3-triazol-2-yl)benzoyl)-6-methylpiperidin-3-yl)-N-(4-cyanopyridin-2-yl)acetamide 
• 1612786-30-7 (2R,5R)-benzyl 5-azido-2-methylpiperidine-1-carboxylate 

Relevant academic research and scientific papers

Investigation of orexin-2 selective receptor antagonists: Structural modifications resulting in dual orexin receptor antagonists

In an ongoing effort to explore the use of orexin receptor antagonists for the treatment of insomnia, dual orexin receptor antagonists (DORAs) were structurally modified, resulting in compounds selective for the OX2R subtype and culminating in the discovery of 23, a highly potent, OX2R-selective molecule that exhibited a promising in vivo profile. Further structural modification led to an unexpected restoration of OX1R antagonism. Herein, these changes are discussed and a rationale for selectivity based on computational modeling is proposed.

FUSED HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS

Fused heteroaryl derivative compounds which are antagonists of orexin receptors are provided. The compounds can be used in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. Also provided is a composition which comprises the compound can be use to prevent or treat such diseases in which orexin receptors are involved.

2-PYRIDYLOXY-3-ESTER-4-ETHER OREXIN RECEPTOR ANTAGONISTS

The present invention is directed to 2-pyridyloxy-3-ester-4-ether compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the 2-pyridyloxy-4-ether compounds described herein in the potential treatment or prev

PIPERIDINYLOXY LACTONE OREXIN RECEPTOR ANTAGONISTS

The present invention is directed to piperidinyloxy lactone compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the piperidinyloxy lactone compounds described herein in the potential treatment or preventi

THIOETHER-PIPERIDINYL OREXIN RECEPTOR ANTAGONISTS

The present invention is directed to thioether-piperidinyl compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the thioether-piperidinyl compounds described herein in the potential treatment or prevention

2-AMINO-3-ESTER-PYRIDYL OREXIN RECEPTOR ANTAGONISTS

The present invention is directed to 2-amino-3-ester pyridyl compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the 2-amino-3-ester pyridyl compounds described herein in the potential treatment or preven

2-PYRIDYLOXY-4-ETHER OREXIN RECEPTOR ANTAGONISTS

The present invention is directed to 2-pyridyloxy-4-ether compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the 2-pyridyloxy-4-ether compounds described herein in the potential treatment or prevention o

HYDROXY-SUBSTITUTED OREXIN RECEPTOR ANTAGONISTS

The present invention is directed to hydroxy compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric dis

2-PYRIDYLAMINO-4-NITRILE-PIPERIDINYL OREXIN RECEPTOR ANTAGONISTS

The present invention is directed to 2-pyridylamino-4-nitrile-piperidinyl compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the 2-pyridylamino-4-nitrile-piperidinyl compounds described herein in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.